Micro RNAs (miRNAs) are a small non-coding type of RNA molecule (18-40 nucleotides in length) that play a functional role in the regulation of RNA silencing and post-transcriptional gene expression. miRNA-Seq enables the investigation of the function of small RNAs and the evaluation of regulatory networks of miRNAs and their target genes. Technical Details Sequencing [...]
ACE Extended Cancer Panel for DNA The ACE Extended Cancer Panel covers a core set of >1,400 cancer-related genes, including clinically-actionable* genes as well as genes that have been identified in the literature as having a role to play in tumorigenesis. The panel provides deep and uniform coverage of genes associated with functional pathways that are [...]
ACE Research Transcriptome The same accuracy and coverage enhancements of the ACE Research Exome (see above) are also incorporated into RNA analysis using our unique ACE Research Transcriptome enrichment protocol. Many clinical studies depend on tissue archives that have been fixed using formalin-fixed, paraffin-embedded (FFPE) procedures. This preservation process makes it difficult to obtain a [...]
ACE Research Exome Using our patented Accuracy and Content Enhanced (ACE) Technology, the ACE Research Exome outperforms conventional exome assays by augmenting coverage across intronic and difficult-to-sequence regions (including regions of high-GC content) of >8,000 biomedically-important genes, including >1,400 cancer-related genes. The application of this technology ensures the delivery of more complete and uniform coverage of [...]
Personalis NeXT Dx™ Test Increasingly, oncologists and pathologists are utilizing information on genomic alterations in solid tumors, such as lung, colon, breast, melanoma, and prostate cancers, to help guide and optimize therapeutic options for patients including enrolling into cancer clinical trials. The Personalis NeXT Dx™ Test provides clinicians with a comprehensive [...]
Specimen Preparation Guide for Clinical Use: FFPE To ensure submitted specimens yield sufficient amounts of extracted DNA and/or RNA for sequencing and analysis, we have provided the following guidelines below for solid tumors. Unacceptable specimens include hematolymphoid malignancies or decalcified bone. FFPE — Specimen Preparation Guidelines for FFPE preparation: [...]
2019 AACR-NCI-EORTC (ANE) Molecular Targets: A comprehensive, highly accurate genomics platform for precision immunotherapy: Simultaneously characterize tumors and the TME from a single FFPE sample While the success of checkpoint blockade has been hugely promising, it’s increasingly apparent that predicting response to immunotherapies and developing new ones requires a more comprehensive approach to tumor [...]
2019 SITC: Comprehensive and accurate prediction of presented neoantigens using ImmunoID NeXT and advanced machine learning algorithms Comprehensive detection of potential neoantigens and accurate prediction of their MHC presentation are critical prerequisites for selecting neoepitopes that can be used for creating personalized cancer vaccines. However, prediction models developed using in-vitro MHC-peptide purification followed by [...]
2019 SITC: T-cell receptor alpha and beta repertoire profiling using an augmented transcriptome The promise of immunotherapy has revealed the need for comprehensive profiling of the tumor and its immune microenvironment. This includes analysis of the T-cell receptor (TCR) repertoire, which has traditionally not been feasible with an exome/transcriptome platform. To address this challenge, [...]
The use of single-analyte biomarkers (e.g. PD-L1 expression) has yielded modest results in the quest to accurately predict which patients are likely to respond (or not) to immunotherapies and their combinations with other treatment modalities. In the immunotherapy age, it’s clear that more effective patient stratification techniques will require the integration of multiple biomarkers that [...]